Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj
Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj
– BEAT AML data highlight the potential for revumenib to advance the current standard of care –– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients –
– 從第二階段協議定義的R/R mNPM1 AML療效人群（N=64）進行的亞組分析顯示，所有主要亞組均有反應，包括重度預處理患者–
– 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort –
– 在滿足第二階段R/R mNPM1 AML隊列有效性評估標準的所有入組患者中，CR+CRh爲26%（20/77），ORR爲48%（37/77）–
– 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML –
– 在BEAt AML試驗中，探索revumenib與venetoclax/azacitidine聯合用於新診斷的mNPM1或KMT2Ar AML，ORR爲100%（37/37），CRc爲95%（35/37）–
– BEAT AML data highlight the potential for revumenib to advance the current standard of care –
– BEAt AML數據凸顯了revumenib在推進當前標準護理方面的潛力–
